Physician profile
Alexander Landfield
NPI 1447451463
$6,912.14
in general payments reported to CMS, 2019-2025
40 companies · $1,890 in 2025
The $1,890 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.36 · 2020: $42.43 · 2021: $337 · 2022: $925 · 2023: $1,536 · 2024: $2,089 · 2025: $1,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,514.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,754.98 | 2021-2025 | |
| Pfizer INC. | $1,483.36 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $636.73 | 2021-2025 | |
| Lilly USA, LLC | $431.96 | 2022-2025 | Emgality, Reyvow, Zepbound |
| Teva Pharmaceuticals USA, INC. | $410.59 | 2021-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Biohaven Pharmaceutical Holding Company Ltd. | $346.42 | 2022 | |
| Neurelis, INC. | $260.41 | 2021-2025 | Valtoco |
| Impel Pharmaceuticals INC. | $131.32 | 2023 | Trudhesa |
| Ucb, INC. | $122.12 | 2023-2025 | Briviact, Nayzilam |
| Genentech USA, INC. | $116.02 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Amgen INC. | $92.86 | 2021-2023 | Aimovig |
| Celgene Corporation | $91.06 | 2022-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $89.56 | 2024-2025 | Hyqvia |
| Biohaven Pharmaceuticals, INC. | $82.02 | 2021 | |
| Livanova USA, INC. | $74.87 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Landfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.